The goal of this randomized clinical trial is to evaluate the clinical and radiographic success of pulpotomy using Neoputty MTA vital primary molars diagnosed with symptomatic irreversible pulpitis.
The main question it aims to answer is:
Will Neoputty MTA pulpotomy have higher clinical and radiographic success in comparison to Endoflas pulpectomy in primary molars with irreversible pulpitis?
Children with spontaneous pain lasting a few seconds to several hours.
Pain is intensified by thermal stimulus and persists after its removal.
Pulp hemorrhage after performing access cavity and deroofing of pulp chamber showing reddish pink healthy pulp tissue.
Radicular pulp health is verified by achieving hemostasis within six minutes of compression using a cotton pellet with 2% sodium hypochlorite.
Unrestorable primary molars.
Primary molars with uncontrolled pulp hemorrhage or pulp necrosis.
Medically compromised patients who have systemic disease.
Uncooperative children who refuse treatment.
Parallel
NeoPUTTY MTA pulpotomy
Procedure/SurgeryNeoputty MTA pulpotomy performed in vital primary molars with symptomatic irreversible pulpitis
Endoflas pulpectomy
Procedure/SurgeryEndoflas pulpectomy in vital primary molars with symptomatic irreversible pulpitis
postoperative pain
postoperative pain will be assessed using the visual analogue scale (VAS) within 24 hours, after 1 week, 3, 6, 9, and 12 months. The patients are asked to point to the face that best represents how they are feeling at the follow-up visits.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
